Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam KPJ, Volkers AG, Wieske L, Stalman EW, Kummer LYL, van Kempen ZLE, Killestein J, Tas SW, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Cristianawati O, Ten Brinke A, Verstegen NJM, van Ham SM, Rispens T, Kuijpers TW, Löwenberg M, Eftimov F; T2B! Immunity against SARS-CoV-2 study group. van Dam KPJ, et al. Among authors: bekkenk mw. BMC Infect Dis. 2023 May 17;23(1):332. doi: 10.1186/s12879-023-08298-6. BMC Infect Dis. 2023. PMID: 37198536 Free PMC article.
SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
van Kempen ZLE, Stalman EW, Steenhuis M, Kummer LYL, van Dam KPJ, Wilbrink MF, Ten Brinke A, van Ham SM, Kuijpers T, Rispens T, Eftimov F, Wieske L, Killestein J; T2B! immunity against SARS-CoV-2 study group. van Kempen ZLE, et al. J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):280-283. doi: 10.1136/jnnp-2022-330100. Epub 2022 Dec 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36564175
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses.
van den Dijssel J, Duurland MC, Konijn VA, Kummer LY, Hagen RR, Kuijper LH, Wieske L, van Dam KP, Stalman EW, Steenhuis M, Geerdes DM, Mok JY, Kragten AH, Menage C, Koets L, Veldhuisen B, Verstegen NJ, van der Schoot CE, van Esch WJ, D'Haens GR, Löwenberg M, Volkers AG, Rispens T, Kuijpers TW, Eftimov F, van Gisbergen KP, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. van den Dijssel J, et al. J Autoimmun. 2024 Apr;144:103175. doi: 10.1016/j.jaut.2024.103175. Epub 2024 Feb 21. J Autoimmun. 2024. PMID: 38387105 Free article.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS-CoV-2 study group. Valk AM, et al. Among authors: bekkenk mw. Allergy. 2024 Mar 4. doi: 10.1111/all.16089. Online ahead of print. Allergy. 2024. PMID: 38439527
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
Verstegen NJM, Hagen RR, Kreher C, Kuijper LH, Dijssel JVD, Ashhurst T, Kummer LYL, Palomares Cabeza V, Steenhuis M, Duurland MC, Jongh R, Schoot CEV, Konijn VAL, Mul E, Kedzierska K, van Dam KPJ, Stalman EW, Boekel L, Wolbink G, Tas SW, Killestein J, Rispens T, Wieske L, Kuijpers TW, Eftimov F, van Kempen ZLE, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. Verstegen NJM, et al. J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224. doi: 10.1136/jnnp-2023-332224. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38548324 Free article.
Expert opinion about laser and intense pulsed light (IPL)-induced leukoderma or vitiligo: a cross-sectional survey study.
Post NF, Van Broekhoven NX, Lommerts A, Bae JM, Bekkenk MW, de Castro CCS, Eleftheriadou V, Esmat S, Ezzedine K, van Geel N, Hamzavi I, Leone G, Pandya AG, Passeron T, Rodrigues MA, Seneschal J, Th'ng S, Wolkerstorfer A. Post NF, et al. Among authors: bekkenk mw. Arch Dermatol Res. 2023 Oct;315(8):2289-2294. doi: 10.1007/s00403-023-02611-8. Epub 2023 Mar 25. Arch Dermatol Res. 2023. PMID: 36964767 Free PMC article.
In-Depth Proteomic Map of Innate Lymphoid Cells from Healthy Human Skin and Blood.
Teunissen MBM, Pilgaard Møller LB, Løvendorf MB, Skov L, Bonefeld CM, Bekkenk MW, Clark RA, Mann M, Dyring-Andersen B. Teunissen MBM, et al. Among authors: bekkenk mw. J Invest Dermatol. 2024 Feb;144(2):316-330.e3. doi: 10.1016/j.jid.2023.07.011. Epub 2023 Aug 5. J Invest Dermatol. 2024. PMID: 37544588 Free article.
102 results